Skip to main navigation

close search window

CING | Nasdaq Listed

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

Header Social TwitterLinkedInFacebookYoutube

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

close search window

Search:

search submit button

A woman pointing something on the monitor while two men watch

Email Alerts

IR Resources

Investor FAQs
Email Alerts
Contact IR

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
Event
News
Weekly Summary

Email

Leave this field blank

eHealth Radio Network: ADHD Through the Lifecycle: Managing Symptoms Over Time

MedCity News: Extending ADHD Coverage for the Entire Active Day

LA Weekly: Three Doctors, 14 Years, and One Mission to Improve ADHD Treatment

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

NPR: ADHD and the Search for a More Balanced Conversation

ADHD Management for the Entire Active Day is Within Reach

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

TwitterLinkedInFacebookYoutube

Contact us

1901 W 47th Place
Kansas City 66205

info@cingulate.com
913-942-2300

© Cingulate^® | PRIVACY POLICY